Vascular aspects of cognitive impairment and dementia

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 11, 2013, Pages 1696-1706

  Wiesmann, Maximilian ^a   Kiliaan, Amanda J ^a   Claassen, Jurgen Ahr ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

animal models; cerebral hemodynamics; cognitive impairment; dementia; diet; hypertension

Indexed keywords

OMEGA 3 FATTY ACID;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BRAIN BLOOD VESSEL; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; MULTIINFARCT DEMENTIA; NONHUMAN; OBESITY; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; VASCULAR AMYLOIDOSIS;

ANIMALS; COGNITION DISORDERS; DEMENTIA, VASCULAR; HEMODYNAMICS; HUMANS; HYPERTENSION; RISK FACTORS; STROKE;

EID: 84887123340     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.159     Document Type: Review

References (145)

1. Ritchie K, Lovestone S. The dementias. Lancet 2002; 360: 1759-1766. (Pubitemid 35447916)
2. Morris JC. The nosology of dementia. Neurol Clin 2000; 18: 773-788. (Pubitemid 32042595)
3. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34: 335-337. (Pubitemid 36206315)
4. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology 1993; 43: 250-260. (Pubitemid 23060253)
5. Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 2013; 1: CD008900.
6. Tang WK, Chan SSM, Chiu HFK, Ungvari GS, Wong KS, Kwok TCY et al. Impact of applying NINDS-AIREN criteria of probable vascular dementia to clinical and radiological characteristics of a stroke cohort with dementia. Cerebrovasc Dis 2004; 18: 98-103. (Pubitemid 39077843)
7. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992; 42: 473.
8. Román GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002; 86: 477-499. (Pubitemid 34810644)
9. Madureira S, Guerreiro M, Ferro JM. Dementia and cognitive impairment three months after stroke. Eur J Neurol 2001; 8: 621-627. (Pubitemid 35015229)
10. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M. Clinical determinants of poststroke dementia. Stroke 1998; 29: 75-81. (Pubitemid 28046945)
11. Inzitari D, Di Carlo A, Pracucci G, Lamassa M, Vanni P, Romanelli M et al. Incidence and determinants of poststroke dementia as defined by an informant interview method in a hospital-based stroke registry. Stroke 1998; 29: 2087-2093. (Pubitemid 28443523)
12. Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 2672-2713.
13. Thal DR, Grinberg LT, Attems J. Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol 2012; 47: 816-824.
14. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996; 383: 707-710. (Pubitemid 26360644)
15. O'Brien JT. Vascular cognitive impairment. Am J Geriatr Psychiatry 2006; 14: 724-733. (Pubitemid 44380064)
16. Grant I, Adams K. Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders. Oxford University Press: USA, 2009.
17. Thieme H, Bayn M, Wurg M, Zange C, Pohl M, Behrens J. Mirror therapy for patients with severe arm paresis after stroke-a randomized controlled trial. Clin Rehabil 2012; 27: 314-324.
18. Rutten-Jacobs LC, Arntz RM, Maaijwee NA, Schoonderwaldt HC, Dorresteijn LD, van Dijk EJ et al. Long-term mortality after stroke among adults aged 18 to 50 years. Cochrane Database Syst Rev 2013; 309: 1136-1144.
19. Alzheimer A. Ü ber einen eigenartigen schweren Erkrankungsproze-der Hirnrinde. Neurologisches Centralblatt 1906; 23: 1129-1136.
20. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer's disease. Lancet 1997; 349: 1546-1549. (Pubitemid 27216376)
21. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F et al. Intraneuronal A[beta]42 accumulation in human brain. Am J Pathol 2000; 156: 15-20. (Pubitemid 30644433)
22. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004; 3: 184-190. (Pubitemid 38232669)
23. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351-357. (Pubitemid 27435070)
24. Braak H, Braak E, Bohl J, Reintjes R. Age, neurofibrillary changes, A[beta]-amyloid and the onset of Alzheimer's disease. Neurosci Lett 1996; 210: 87-90. (Pubitemid 26180122)
25. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid [beta]-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112. (Pubitemid 46432529)
26. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987; 18: 311-324. (Pubitemid 17059655)
27. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold K-H et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 2001; 21: 1619-1627. (Pubitemid 32182202)
28. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992; 42: 1681.
29. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991; 12: 295-312.
30. Gorelick PB. Risk factors for vascular dementia and alzheimer disease. Stroke 2004; 35: 2620-2622. (Pubitemid 39458352)
31. Yu J-G, Zhou R-R, Cai G-J. From hypertension to stroke: mechanisms and potential prevention strategies. CNS Neurosci Ther 2011; 17: 577-584.
32. Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. Int J Stroke 2012; 7: 61-73.
33. Tu JV. Reducing the global burden of stroke: INTERSTROKE. Lancet 2010; 376: 74-75.
34. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
35. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764. (Pubitemid 27387202)
36. Palmer AJ, Bulpitt CJ, Fletcher AE, Beevers DG, Coles EC, Ledingham JG et al. Relation between blood pressure and stroke mortality. Hypertension 1992; 20: 601-605.
37. Schneider JA. High blood pressure and microinfarcts: a link between vascular risk factors, dementia, and clinical Alzheimer's disease. J Am Geriatr Soc 2009; 57: 2146-2147.
38. Savva GM, Stephan BCM. Group tAsSVDSR. Epidemiological studies of the effect of stroke on incident dementia. Stroke 2010; 41: e41-e46.
39. Bé jot Y, Aboa-Eboulé C, Durier J, Rouaud O, Jacquin A, Ponavoy E et al. Prevalence of early dementia after first-ever stroke. Stroke 2011; 42: 607-612.
40. Whitehead SN, Massoni E, Cheng G, Hachinski VC, Cimino M, Balduini W et al. Triflusal reduces cerebral ischemia induced inflammation in a combined mouse model of Alzheimer's disease and stroke. Brain Res 2010; 1366: 246-256.
41. Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC et al. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to establish a registry for Alzheimer's disease. Neurology 1998; 51: 159-162. (Pubitemid 28345377)
42. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-817. (Pubitemid 27111317)
43. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215-1222. (Pubitemid 36359297)
44. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342. (Pubitemid 28402270)
45. Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Beiser A, Au R et al. Framingham stroke risk profile and lowered cognitive performance. Stroke 2004; 35: 404-409. (Pubitemid 38174420)
46. Kalaria R. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 2002; 203-204: 29-34. (Pubitemid 35287372)
47. Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 2012; 322: 141-147.
48. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-1451. (Pubitemid 32575406)
49. Skoog I, Nilsson L, Persson G, Lernfelt B, Landahl S, Palmertz B et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145. (Pubitemid 126512042)
50. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC et al. Polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002; 155: 487-495. (Pubitemid 34208040)
51. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia-A double edged sword. Ageing Res Rev 2009; 8: 61-70.
52. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006; 103: 18727-18732. (Pubitemid 44913478)
53. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74. (Pubitemid 41790697)
54. Panza F, D'Introno A, Colacicco AM, Basile AM, Capurso C, Kehoe PG et al. Vascular risk and genetics of sporadic late-onset Alzheimer's disease. J Neural Transm 2004; 111: 69-89. (Pubitemid 38177819)
55. Latchman DS. Herpes simplex virus and risk of Alzheimer's disease. Lancet 1997; 349: 1101.
56. Breteler MMB, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 1994; 308: 1604-1608. (Pubitemid 24181869)
57. Posner HB, Tang M-X, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2000; 58: 1175-1181.
58. Kilander L, Andrén B, Nyman H, Lind L, Boberg M, Lithell H. Atrial fibrillation is an independent determinant of low cognitive function. Stroke 1998; 29: 1816-1820.
59. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MMB. Association of diabetes mellitus and dementia: the Rotterdam study. Diabetologia 1996; 39: 1392-1397. (Pubitemid 26356072)
60. Kivipelto M, Helkala E-L, Laakso MP, Hänninen T, Hallikainen M, Alhainen K et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-1451. (Pubitemid 32575406)
61. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49-55. (Pubitemid 30224785)
62. Nagata KEN, Sato M, Satoh Y, Watahiki Y, Kondoh Y, Sugawara M et al. Hemodynamic aspects of Alzheimer's Disease. Ann N Y Acad Sci 2002; 977: 391-402. (Pubitemid 35418181)
63. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-360. (Pubitemid 38568496)
64. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab 2008; 7: 476-484. (Pubitemid 351729202)
65. Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke 2009; 40: S40-S44.
66. Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008; 9: 169-181. (Pubitemid 351272665)
67. Zlokovic BV. The Blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
68. Kalaria RN. Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer's disease. Neurobiol Aging 2009; 30: 1512-1514.
69. Selnes OA, Vinters HV. Vascular cognitive impairment. Nat Clin Pract Neurol 2006; 2: 538-547. (Pubitemid 44445810)
70. Modrick ML, Didion SP, Sigmund CD, Faraci FM. Role of oxidative stress and AT1 receptors in cerebral vascular dysfunction with aging. Am J Physiol Heart Circ Physiol 2009; 296: H1914-H1919.
71. Park L, Anrather J, Girouard H, Zhou P, Iadecola C. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab 2007; 27: 1908-1918. (Pubitemid 350129160)
72. Petrovitch H, Ross GW, Steinhorn SC, Abbott RD, Markesbery W, Davis D et al. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol 2005; 57: 98-103. (Pubitemid 40053320)
73. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013; 136: 2697-2706.
74. Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993; 138: 353-364. (Pubitemid 23289288)
75. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-154. (Pubitemid 27039193)
76. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment. Hypertension 1998; 31: 780-786.
77. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846-1851. (Pubitemid 26001260)
78. Ruitenberg A, Skoog I, Ott A, Aevarsson O, Witteman JCM, Lernfelt B et al. Blood pressure and risk of dementia: results from the rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12: 33-39. (Pubitemid 32008939)
79. Sharp SI, Aarsland D, Day S, Sønnesyn H. Alzheimer's society vascular dementia systematic review GBallard C. . Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 2011; 26: 661-669.
80. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 2006; 28: 605-611. (Pubitemid 44444422)
81. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population. Neurology 1995; 45: 1161-1168.
82. Gentile MT, Poulet R, Pardo AD, Cifelli G, Maffei A, Vecchione C et al. b-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging 2009; 30: 222-228.
83. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: A community-based, longitudinal study. Stroke 2003; 34: 594-599. (Pubitemid 36307377)
84. Hanon O, Haulon S, Lenoir H, Seux M-L, Rigaud A-S, Safar M et al. Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke 2005; 36: 2193-2197. (Pubitemid 41429244)
85. Carnevale D, Lembo G. 'Alzheimer-like' pathology in a murine model of arterial hypertension. Biochem Soc Trans 2011; 39: 939-944.
86. Poulet R, Gentile MT, Vecchione C, Distaso M, Aretini A, Fratta L et al. Acute hypertension induces oxidative stress in brain tissues. J Cereb Blood Flow Metab 2005; 26: 253-262.
87. Arendash GW, Su GC, Crawford FC, Bjugstad KB, Mullan M. Intravascular bamyloid infusion increases blood pressure: implications for a vasoactive role of b-amyloid in the pathogenesis of Alzheimer's disease. Neurosci Lett 1999; 268: 17-20. (Pubitemid 29292534)
88. Matsubayashi K, Shimada K, Kawamoto A, Ozawa T. Incidental brain lesions on magnetic resonance imaging and neurobehavioral functions in the apparently healthy elderly. Stroke 1992; 23: 175-180.
89. Chodosh EH, Foulkes MA, Kase CS, Wolf PA, Mohr JP, Hier DB et al. Silent stroke in the NINCDS Stroke Data Bank. Neurology 1988; 38: 1674.
90. Jendroska K, Poewe W, Daniel SE, Pluess J, Iwerssen-Schmidt H, Paulsen J et al. Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol 1995; 90: 461-466.
91. Jendroska K, Hoffmann OM, Patt S. Amyloid b Peptide and Precursor Protein (APP) in Mild and Severe Brain Ischemia. Ann N Y Acad Sci 1997; 826: 401-405. (Pubitemid 27478062)
92. Kalaria RN, Bhatti SU, Palatinsky EA, Pennington DH, Shelton ER, Chan HW et al. Accumulation of the beta amyloid precursor protein at sites of ischemic injury in rat brain. Neuroreport 1993; 4: 211-214. (Pubitemid 23080879)
93. Nakamura Y, Takeda M, Niigawa H, Hariguchi S, Nishimura T. Amyloid b-protein precursor deposition in rat hippocampus lesioned by ibotenic acid injection. Neurosci Lett 1992; 136: 95-98.
94. Pottier C, Wallon D, Lecrux AR, Maltete D, Bombois S, Jurici S et al. Amyloid-b Protein Precursor Gene Expression in Alzheimer's Disease and Other Conditions. J Alzheimers Dis 2012; 28: 561-566.
95. Okamoto Y, Yamamoto T, Kalaria R, Senzaki H, Maki T, Hase Y et al. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 2012; 123: 381-394.
96. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C et al. Cerebrovascular lesions induce transient b-amyloid deposition. Brain 2011; 134: 3697-3707.
97. Okamoto Y, Ihara M, Fujita Y, Ito H, Takahashi R, Tomimoto H. Cortical microinfarcts in Alzheimer's disease and subcortical vascular dementia. Neuroreport 2009; 20: 990-996.
98. Suter O-C, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 2002; 33: 1986-1992. (Pubitemid 34840055)
99. Whitehead SN, Cheng G, Hachinski VC, Cechetto DF. Progressive increase in infarct size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid. Stroke 2007; 38: 3245-3250. (Pubitemid 350175744)
100. Sabayan B, Jansen S, Oleksik AM, van Osch MJP, van Buchem MA, van Vliet P et al. Cerebrovascular hemodynamics in Alzheimer's disease and vascular dementia: a meta-analysis of transcranial Doppler studies. Ageing Res Rev 2012; 11: 271-277.
101. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002; 9: 61-68. (Pubitemid 34174565)
102. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 2002; 283: H315-H323. (Pubitemid 34705353)
103. Claassen JAHR, Zhang R. Cerebral autoregulation in Alzheimer's disease. J Cereb Blood Flow Metab 2011; 31: 1572-1577.
104. Whitmer RA, Gunderson EP, Barrett-Connor E, Charles P, Quesenberry J, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005; 330: 1360.
105. Luchsinger J, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 2004; 6: 261-266. (Pubitemid 39359464)
106. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006; 5: 735-741. (Pubitemid 44205512)
107. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008; 7: 812-826.
108. Aarsland D, Sardahaee FS, Anderssen S, Ballard C. The Alzheimer's Society Systematic Review. Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health 2010; 14: 386-395.
109. Ravaglia G, Forti P, Lucicesare A, Pisacane N, Rietti E, Bianchin M et al. Physical activity and dementia risk in the elderly: findings from a prospective Italian study. Neurology 2008; 70: 1786-1794. (Pubitemid 351653964)
110. Dichgans M, Zietemann V. Prevention of vascular cognitive impairment. Stroke 2012; 43: 3137-3146.
111. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Hoefnagels WH, Beekman AT et al. Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2008; 88: 706-713.
112. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A et al. O-3 fatty acid treatment in 174 patients with mild to moderate alzheimer disease: omegad study: a randomized double-blind trial. Arch Neurol 2006; 63: 1402-1408. (Pubitemid 44547551)
113. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010; 6: 456-464.
114. Hooijmans CR, Pasker-de Jong PCM, de Vries RBM, Ritskes-Hoitinga M. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's Disease: A Systematic Review And Meta-Analysis. J Alzheimers Dis 2012; 28: 191-209.
115. Witte AV, Kerti L, Hermannstädter HM, Fiebach JB, Schreiber SJ, Schuchardt JP et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex 2013.
116. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88: 523-533. (Pubitemid 23228051)
117. Appel Lj, Miller 3rd ER, Seidler AJ, Whelton PK. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med 1993; 153: 1429-1438. (Pubitemid 23191050)
118. Kimura S, Saito H, Minami M, Togashi H, Nakamura N, Ueno K et al. Docosahexaenoic acid attenuated hypertension and vascular dementia in stroke-prone spontaneously hypertensive rats. Neurotoxicol Teratol 2002; 24: 683-693. (Pubitemid 35013528)
119. Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens 2005; 23: 475-481. (Pubitemid 40684701)
120. Zhang W, Liu A-J, Yi-Ming W, Liu J-G, Shen F-M, Su D-F. Pressor and non-pressor effects of sodium loading on stroke in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2008; 35: 83-88. (Pubitemid 350197685)
121. Kuller LH, Shemanski L, Manolio T, Haan M, Fried L, Bryan N et al. Relationship between ApoE, MRI findings, and cognitive function in the cardiovascular health study. Stroke 1998; 29: 388-398. (Pubitemid 28086681)
122. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S et al. Guidelines for the primary prevention of stroke. Stroke 2011; 42: 517-584.
123. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR et al. Fish consumption and incidence of stroke. Stroke 2004; 35: 1538-1542.
124. de Goede J, Verschuren WMM, Boer JMA, Kromhout D, Geleijnse JM. Genderspecific associations of Marine n-3 fatty acids and fish consumption with 10-year incidence of stroke. PLoS ONE 2012; 7: e33866.
125. Pan H-C, Kao T-K, Ou Y-C, Yang D-Y, Yen Y-J, Wang C-C et al. Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J Nutr Biochem 2009; 20: 715-725.
126. Ozen O, Cosar M, Sahin O, Fidan H, Eser O, Mollaoglu H et al. The protective effect of fish n-3 fatty acids on cerebral ischemia in rat prefrontal cortex. Neurol Sci 2008; 29: 147-152. (Pubitemid 352003649)
127. Bazan NG, Eady TN, Khoutorova L, Atkins KD, Hong S, Lu Y et al. Novel aspirintriggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Exp Neurol 2012; 236: 122-130.
128. Larsson SC, Virtamo J, Wolk A. Dietary fats and dietary cholesterol and risk of stroke in women. Atherosclerosis 2012; 221: 282-286.
129. Gardener H, Wright CB, Gu Y, Demmer RT, Boden-Albala B, Elkind MS et al. Mediterranean-style diet and risk of ischemic stroke, myocardial infarction, and vascular death: the Northern Manhattan Study. Am J Clin Nutr 2011; 94: 1458-1464.
130. Oudin A, Wennberg M. Fish Consumption and ischemic stroke in Southern Sweden. Nutr J 2011; 10: 109.
131. de Goede J, Verschuren WMM, Boer JMA, Kromhout D, Geleijnse JM. Alpha-linolenic acid intake and 10-Year incidence of coronary heart disease and stroke in 20,000 middle-aged men and women in The Netherlands. PLoS ONE 2011; 6: e17967.
132. Nguemeni C, Delplanque B, Rovère C, Simon-Rousseau N, Gandin C, Agnani G et al. Dietary supplementation of alpha-linolenic acid in an enriched rapeseed oil diet protects from stroke. Pharmacol Res 2010; 61: 226-233.
133. Arab L, Liu W, Elashoff D. Green and black tea consumption and risk of stroke. Stroke 2009; 40: 1786-1792.
134. Mogi M, Li J-M, Iwanami J, Min L-J, Tsukuda K, Iwai M et al. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48: 141-148. (Pubitemid 44297536)
135. Yamada K, Uchida S, Takahashi S, Takayama M, Nagata Y, Suzuki N et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res 2010; 1352: 176-186.
136. Muller M, van der Graaf Y, Visseren FL, Mali WPTM, Geerlings MI. for the SSG. Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann Neurol 2012; 71: 825-833.
137. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K et al. Angiotensin receptor blocker prevented b-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54: 1345-1352.
138. Tsukuda K, Mogi M, Iwanami J, Min L-J, Sakata A, Jing F et al. Cognitive deficit in Amyloid-b-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-g activation. Hypertension 2009; 54: 782-787.
139. Jing F, Mogi M, Sakata A, Iwanami J, Tsukuda K, Ohshima K et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab 2012; 32: 248-255.
140. Shlyakhto E. Observational study on cognitive function and systolic blood pressure reduction (OSCAR): preliminary analysis of 6-month data from410 000 patients and review of the literature. Curr Med Res Opin 2007; 23: S13-S18.
141. Iwai M, Inaba S, Tomono Y, Kanno H, Iwanami J, Mogi M et al. Attenuation of focal brain ischemia by telmisartan, an angiotensin II Type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens Res 2008; 31: 161-168. (Pubitemid 351325628)
142. Shiraishi J, Sawada T, Koide M, Yamada H, Matsubara H. Cardio-Cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study). Am J Cardiol 2012; 109: 1308-1314.
143. Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension. The study on cognition and prognosis in the elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175-1180. (Pubitemid 39208870)
144. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X et al. Valsartan lowers brain bamyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402. (Pubitemid 350096995)
145. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 2009; 7: 250-261.